TNXP - New to The Street Announces TV Episode 560 with its Five Business Guest Interviews Airs as Sponsored Programming on Bloomberg TV Tonight Thursday March 7 2024 at 9:30 PM PT | Benzinga
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its business show that will air as a sponsored program on Bloomberg TV tonight, Thursday, March 7, 2024, at 9:30 PM PT.
New to The Street's TV episode 560 will air the following five (5) business interviews:
1)."Game Changers" segment interview with PetVivo Holdings, Inc.'s (NASDAQ:PETV) (NASDAQ:PETVW) () John Lai, CEO/President.
2). Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s euticals, Inc.'s (NASDAQ:TNXP) () interview with Dr. Seth Lederman, MD, Chairman and CEO.
3). Sustainable Solutions - VRM BioLogik® Group's (VRM) interview with Ken Bellamy, Founder and President.
4). Financial Marketplace Strategies – Blue Castle Ventures LTD's () interviews with David Rojas, CEO/Founder.
5). "Sekur Privacy & Sekur Security – Weekly Hack" segment with internet privacy expert Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) () (Sekur®).
Episode 560
New to The Street airs its "Game Changers" segment with TV Host and Multi-media Journalist Ana Berry, who talks with John Lai, CEO/President of PetVivo Holdings, Inc. (NASDAQ:PETV) (NASDAQ:PETVW) () ("PetVivo"). With creative therapeutic medical innovations for pets, PETV is a "Game Changer." Owners of dogs, cats, and horses are seeing remarkable results when using the Company's SPRYNG™ with OsteoCushion Technology ("SPRYNG™"), an intra-articular injectable veterinary medical device consisting of cellular matrix microparticles. Veterinarians are increasingly using the product as an alternative to surgery, helping pet owners manage pets with osteoarthritis and other joint-related ailments. John goes over three corporate milestones. First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease. The next milestone was the Company's ability to attract Covetrus North America, LLC, another largest veterinarian medical distributor; now, the three largest medical distributors carry SPRYNG™. In January 2024, the third milestone veterinarian doctors who were keynote speakers at the Veterinary Meeting & Expo (VMX) conference in Orlando, Florida, endorsing their successful use of the Company's SPRYNG™ product in small animal cases. Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses. The Company expects sales increases for product uses for small pets, dogs, and cats, as these recent studies, presentations, and distributors are educating pet owners and vets about SPRYNG™ positive treatment outcomes. The Company has five more pending studies, with expected results reported before the conclusion of 2024. PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. - https://petvivo.com/ & Spryng with OsteoCushion Technology - https://www.sprynghealth.com/.
From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD, Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ:TNXP) () ("Tonix"), talks with New to The Street's TV Host Jane King about the Company's successful completion of Phase 3 studies on its fibromyalgia drug. Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia. The drug is a non-opioid, non-addictive painkiller. Since 2009, there have been no new fibromyalgia drugs available in the marketplace. Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in treatment success. Competitor drugs cause sleeplessness and low energy. Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish patient fatigue. The side effects are minimal, with around 3% of patients experiencing headaches and some drowsiness. Administered as a sublingual tablet, Tonmya™ has caused tongue numbness in a few patients. Patients take the drug at bedtime, which can block brain signals that are often associated with pain, and the drug has shown improved sexual functionality. Dr. Lederman expects the Company to submit its full report to the FDA for market approval sometime during the first half of 2024, with a full approval expectation sometime in 2025. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. - https://www.tonixpharma.com/.
New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President. As a leading technology company utilizing microbial formulations, VRM is creating solutions for significant organic waste mitigation and recycling issues facing the planet. Ken explains that using organic catalysts and waste materials, the Company develops technologies that improve soils, increasing agricultural productivity and water conservation. VRM offers solutions to small growers and large governmental organizations to recycle organic waste into usable nutrient-rich products. Ken talks about VRM's participation in the COP 28 event in Dubai, where they showcased innovative solutions and case studies. VRM had the privilege of delivering a speech on behalf of the Government of Indonesia at the event, emphasizing the government's six years of experience and initiatives using VRM's innovative, environmentally sound technologies, products, and services. Currently, VRM is working with nine other countries seeking environmentally sound solutions to significantly improve waste management conversion into functional products. Global private and public ...